*American Association for the Study of Liver Diseases

Triple therapy consisting of a protease inhibitor combined with pegylated interferon alfa and ribavirin (PR) may increase sustained viral response (SVR12), but it may be more difficult to tolerate than PR therapy alone.

As the worldwide disease burden increases and the need for expanded access to care rises concomitantly, primary care clinics utilizing an interdisciplinary staffing model offer a promising alternative to treating patients with hepatitis C (HCV).

Watchful waiting in patients with chronic hepatitis C (HCV) genotype 1 infection may increase the number of advanced liver disease cases, according to a poster presented at the 2013 American Association for the Study of Liver Disease (AASLD) meeting held in Washington, DC.

Study results presented at The Liver Meeting 2012 show the experimental treatment leads to high rates of viral clearance in patients with hepatitis C, even in those with compensated cirrhosis.

According to study results presented at The Liver Meeting 2012, combination treatment with ribavirin and the uridine nucleotide analog sofosbuvir achieved high rates of sustained viral response in a range of patients with hepatitis C.

The development of direct acting antivirals has led to significant improvement in treatment outcomes for many patients with hepatitis C. New research has also improved management of treatment-related anemia, helped streamline standard therapy, and identified promising new approaches to interferon-free treatment.

Study results presented at The Liver Meeting 2012 show that administering two direct-acting antivirals results in a high rate of sustained virologic response in patients with hepatitis C who failed previous treatment with ribavirin/peginterferon.

Hospitalized patients with cirrhosis who also have hyponatremia often receive no treatment, or ineffective treatment, and are often discharged with their serum sodium too low.

Data presented at The Liver Meeting show that treatment with a combination of three direct-acting antivirals plus ribavirin achieved virus control in almost all patients with hepatitis C in a phase II study.

Study results presented at The Liver Meeting (AASLD 2012 annual meeting) show that consuming small amounts of alcohol can have net positive cardiovascular health benefits for some patients with non-alcoholic fatty liver disease.

Boceprevir and telaprevir offer improved clinical benefits to patients with hepatitis C, but a variety of racial, genetic, and other biological factors can influence treatment outcomes.

Study results presented at The Liver Meeting (2012 AASLD annual meeting) show that treatment with tenofovir disoproxil difumarate is safe and effective in this patient population.